Company attributes
Industry
Location
Pitchbook URL
Total Funding Amount (USD)
177,000,000
Latest Funding Round Date
August 16, 2021
Latest Funding Type
Other attributes
Company Operating Status
Active
Contact Page URL
Latest Funding Round Amount (USD)
157,000,000
Overview
GentiBio is a biotherapeutics company created by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates technologies designed to restore immune tolerance and overcome other limitations in regulatory T-cell therapeutics.
GentiBio was launched in 2020 by Adel Nada, Chandra Patel, and Andy Walker. The company has offices in Seattle, Washington and Cambridge, Massachusetts.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.
